ATRC

Company Overview — What Does AtriCure, Inc. Do?

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. AtriCure, Inc. (ATRC) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael H. Carrel and employs approximately 1,050 people, headquartered in MASON, Ohio. With a market capitalization of $1.4B, ATRC is one of the notable companies in the Healthcare sector.

AtriCure, Inc. (ATRC) Stock Rating — Reduce (April 2026)

As of April 2026, AtriCure, Inc. receives a Reduce rating with a composite score of 40.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ATRC ranks #2,380 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AtriCure, Inc. ranks #290 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATRC Stock Price and 52-Week Range

AtriCure, Inc. (ATRC) currently trades at $28.23. The stock gained $0.18 (0.6%) in the most recent trading session. The 52-week high for ATRC is $43.18, which means the stock is currently trading -34.6% from its annual peak. The 52-week low is $28.29, putting the stock -0.2% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is ATRC Overvalued or Undervalued? — Valuation Analysis

AtriCure, Inc. (ATRC) carries a value factor score of 35/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.97x, versus the sector average of 2.75x. The price-to-sales ratio is 2.87x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ATRC trades at 79.55x EV/EBITDA, versus 6.34x for the sector.

At current multiples, AtriCure, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AtriCure, Inc. Profitability — ROE, Margins, and Quality Score

AtriCure, Inc. (ATRC) earns a quality factor score of 45/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -4.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.2% versus the sector average of -33.1%.

On a margin basis, AtriCure, Inc. reports gross margins of 75.0%, compared to 71.5% for the sector. The operating margin is -3.9% (sector: -66.1%). Net profit margin stands at -4.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATRC Debt, Balance Sheet, and Financial Health

AtriCure, Inc. has a debt-to-equity ratio of 33.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.96x, indicating strong short-term liquidity. Total debt on the balance sheet is $62M. Cash and equivalents stand at $148M.

ATRC has a beta of 0.95, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AtriCure, Inc. is 58/100, reflecting average volatility within the normal range for its sector.

AtriCure, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AtriCure, Inc. reported revenue of $510M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-21M. Gross margin was 75.0%. Operating income came in at $-19M.

In FY 2025, AtriCure, Inc. reported revenue of $535M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-11M. Gross margin was 75.0%. Revenue grew 14.9% year-over-year compared to FY 2024. Operating income came in at $-9M.

In Q3 2025, AtriCure, Inc. reported revenue of $134M and earnings per share (EPS) of $-0.01. Net income for the quarter was $-267,000. Gross margin was 75.5%. Revenue grew 15.8% year-over-year compared to Q3 2024. Operating income came in at $208,000.

In Q2 2025, AtriCure, Inc. reported revenue of $136M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-6M. Gross margin was 74.5%. Revenue grew 17.1% year-over-year compared to Q2 2024. Operating income came in at $-6M.

Over the past 8 quarters, AtriCure, Inc. has demonstrated a growth trajectory, with revenue expanding from $116M to $510M. Investors analyzing ATRC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATRC Dividend Yield and Income Analysis

AtriCure, Inc. (ATRC) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATRC Momentum and Technical Analysis Profile

AtriCure, Inc. (ATRC) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

ATRC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AtriCure, Inc. (ATRC) ranks #290 out of 838 stocks based on the Blank Capital composite score. This places ATRC in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATRC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATRC vs S&P 500 (SPY) comparison to assess how AtriCure, Inc. stacks up against the broader market across all factor dimensions.

ATRC Next Earnings Date

No upcoming earnings date has been announced for AtriCure, Inc. (ATRC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATRC? — Investment Thesis Summary

The quantitative profile for AtriCure, Inc. suggests caution. The value score of 35/100 indicates premium valuation. Momentum is weak at 29/100, a headwind for near-term performance.

In summary, AtriCure, Inc. (ATRC) earns a Reduce rating with a composite score of 40.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATRC stock.

Related Resources for ATRC Investors

Explore more research and tools: ATRC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATRC head-to-head with peers: ATRC vs AZN, ATRC vs SLGL, ATRC vs VMD.